-----BEGIN PRIVACY-ENHANCED MESSAGE-----Proc-Type: 2001,MIC-CLEAROriginator-Name: webmaster@www.sec.govOriginator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQABMIC-Info: RSA-MD5,RSA, R0jgAohDMmJ7M/a7ZHOYTeVa07X3aGZYpKpfDAPRQlO7N7uyDY6/grlH8Ikbs3p3 Q8wE9wZjHXSfTPFbQZmYXw==

0000950123-10-013729.txt : 201002170000950123-10-013729.hdr.sgml : 2010021720100217163057ACCESSION NUMBER:0000950123-10-013729CONFORMED SUBMISSION TYPE:DEFA14APUBLIC DOCUMENT COUNT:12FILED AS OF DATE:20100217DATE AS OF CHANGE:20100217EFFECTIVENESS DATE:20100217

FILER:

COMPANY DATA:COMPANY CONFORMED NAME:BIOGEN IDEC INC.CENTRAL INDEX KEY:0000875045STANDARD INDUSTRIAL CLASSIFICATION:BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]IRS NUMBER:330112644STATE OF INCORPORATION:DEFISCAL YEAR END:1231

FILING VALUES:FORM TYPE:DEFA14ASEC ACT:1934 ActSEC FILE NUMBER:000-19311FILM NUMBER:10613172

BUSINESS ADDRESS:STREET 1:14 CAMBRIDGE CENTERCITY:CAMBRIDGESTATE:MAZIP:02142BUSINESS PHONE:6176792000

MAIL ADDRESS:STREET 1:14 CAMBRIDGE CENTERCITY:CAMBRIDGESTATE:MAZIP:02142

FORMER COMPANY:FORMER CONFORMED NAME:BIOGEN IDEC INCDATE OF NAME CHANGE:20031112

FORMER COMPANY:FORMER CONFORMED NAME:IDEC PHARMACEUTICALS CORP / DEDATE OF NAME CHANGE:19970530

DEFA14A1b79481defa14a.htmDEFA14A

defa14a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OFTHE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant Filed by a Party other than the Registrant oCheck the appropriate box:oPreliminary Proxy Statement

o Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2))

o Definitive Proxy Statement

o Definitive Additional Materials

Soliciting Material Pursuant to 240.14a-12

BIOGEN IDEC INC.

(Name of Registrant as Specified In Its Charter)

N.A.(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

o Fee computed on table below per Exchange Act Rules14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transactioncomputed pursuant to Exchange Act Rule0-11 (set forth theamount on which the filing fee is calculated and state how itwas determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

o Fee paid previously with preliminary materials.

o Check box if any part of the fee is offset as provided by Exchange Act Rule0-11(a)(2) and identify thefiling for which the offsetting fee was paid previously. Identify the previous filing by registrationstatement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

Investor Presentation

February 17, 2010

This presentation includes forward-looking statements about:

our strategy for maximizing shareholder value

the ability to improve the benefit-risk profile of TYSABRI(r) and drive future growth

ongoing development initiatives and growth strategies for our marketed products

the anticipated development and timing of programs in our clinical pipeline and regulatory actions

These statements are based on our current beliefs and expectations and involve risks and uncertainties that could cause actual results todiffer materially from those which we expect. Important factors which could cause actual results to differ from our expectations and whichcould negatively impact our financial position and results of operations include our dependence on our three principal products, AVONEX(r),RITUXAN(r) and TYSABRI(r), the importance of market acceptance and successful sales growth of TYSABRI(r), uncertainty of success incommercializing other products, the occurrence of adverse safety events with our products, competitive pressures, changes in theavailability of reimbursement for our products, our dependence on collaborations over which we may not always have full control, failure toexecute our growth initiatives, failure to comply with government regulation and possible adverse impact of changes in such regulation,problems with our manufacturing processes and our reliance on third parties, charges and other costs relating to our properties, fluctuationsin our effective tax rate, our ability to attract and retain qualified personnel, the risks of doing business internationally, representation byactivist shareholders, our ability to protect our intellectual property rights and the cost of doing so, product liability claims, fluctuations in ouroperating results, credit and financial market conditions, the market, interest and credit risks associated with our portfolio of marketablesecurities, our level of indebtedness, environmental risks, aspects of our corporate governance and collaborations and the other risks anduncertainties that are described in the Risk Factors section of our annual report on Form 10-K and in other reports we file with the SEC.Forward-looking statements, like all statements in this presentation, speak only as of the date of this presentation (unless another date isindicated). Unless required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as aresult of new information, future events, or otherwise.

Biogen Idec and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders ofBiogen Idec in connection with the Company's 2010 annual meeting of stockholders. The names, affiliations and interests of suchindividuals may be found in Biogen Idec's Annual Report on Form 10-K for the year ended December 31, 2009 and its proxy statement forthe 2009 Annual Meeting, each of which are filed with the SEC. To the extent holdings of Biogen Idec securities have changed since suchdocuments were filed, such changes have been or will be reflected in Statements of Change in Ownership on Forms 3 and 4 filed with theSEC. Additional information regarding such individuals will be included in the Company's proxy statement in connection with theCompany's 2010 annual meeting of stockholders when such document is filed with the SEC. Biogen Idec files annual, quarterly and specialreports with the SEC. The proxy statements and other reports, when available, can be obtained free of charge at the SEC's web site atwww.sec.gov or from Biogen Idec at www.biogenidec.com. Biogen Idec stockholders are advised to read carefully the proxy statementrelating to the Company's 2010 annual meeting of stockholders and any other relevant documents filed by the Company with the SEC whenthey become available before making any voting or investment decision, because they will contain important information. The Company'sproxy statement will also be available for free by writing to Biogen Idec Inc., 14 Cambridge Center, Cambridge, MA 02142. In addition,copies of the proxy materials, including the Company's white proxy card, may be requested after they have been filed with the SEC from ourproxy solicitor, MacKenzie Partners, Inc., by toll-free telephone at 1-800-322-2885 or by e-mail at proxy@mackenziepartners.com.

Forward Looking Statements and Important Information

2009 in Review

TYSABRI achieved 'blockbuster' status

Late stage MS pipeline advanced and expanded

Revenue grew despite headwinds

Operating margin reached nearly 40%

$1 billion stock buyback initiated

13

Disciplined Use ofCash

Extend AVONEX

and RITUXAN

through Lifecycle

Management

Accelerate

TYSABRI

Growth

Advance our Pipeline

SHAREHOLDER

VALUE

Key Levers to Maximize Shareholder Value

TYSABRI's Blockbuster Year 2003 2004 2005 2006 2007 FYE 2008 FYE 2009 TYSABRI U.S. Patients on Therapy 86 99 25 218 20100 24500 35 344 37600 48800 TYSABRI International Patients on Therapy 73 101 10 126 16900 23700 600 600 test

+30%

Patients on Therapy

+30% 2003 2004 2005 2006 2007 FYE 2008 FYE 2009 TYSABRI In Market U.S. Sales (in $ millions) 86 99 25 218 421.6 508.5 35 344 813 1059.2 TYSABRI In Market International Sales (in $ millions) 73 101 10 126 391.4 550.7

In-Market Revenue ($M)

= U.S.

= ROW

= TRIALS

Viral coat protein(VP1) variants

Regulatoryregion JC Virusvariants

Research to Reduce PML Risk and

Improve Outcomes

6

Management

Prediction and Prevention

Viral Factors

Patient Factors

NatalizumabRemoval

Stop DiseaseProgression

JC Virus Antibody Test

Prior Treatment WithImmunosuppressants

Natalizumab MOA

JCV-specific T-cellfunction

Plasma Exchange(PLEX)

Anti-JCV drugscreening

Mefloquineclinical trial

JC Virus Antibody Test

7

ELISA assay

JC virus antibody detected in 50% to60% of adults

All TYSABRI-treated patients whodeveloped PML, for whom sampleswere available prior to diagnosis(n=11), were anti-JCV antibodypositive

Additional evaluations are plannedto define the potential utility of theassay for PML risk stratification

Note: Two recent studies supporting JCV seroprevalence below 60% include: Prevalence estimate of 38% found by Kean, Rao, Wang,and Garcea (2009), "Seroepidemiology of human polyomaviruses." PLoS Pathog, 5(3):e1000363

Prevalence estimate of 58% found by Egli, Infanti, Dumoulin, Buser, Samaridis, Stebler, Gosert, and Hirsch, "Prevalence ofPolyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors." The Journal of Infectious Diseases 2009;199:837-846

Initiative Objective(s) Switching study vs. Copaxone(r) and Rebif(r) Reinforce efficacyDemonstrate benefit of switching earlyDemonstrate TYSABRI should be first choice switch therapy when you need more efficacy Geographic Expansion Expand market - increased footprint from 38 to 45 countries between 2008 and 2009. Potential growth in Asia, Latin America, Eastern Europe and Middle East Subcutaneous formulation Provide another dosing option for TYSABRI patients SPMS Indication Expand marketReinforce efficacy

Driving Future TYSABRI Growth

Note: Copaxone(r) is a registered trademark of Teva Pharmaceutical Industries Limited andRebif(r) is a registered trademark of EMD Serono, Inc. or its affiliates

AVONEX Franchise Durability 2009 2010+ Granted method of use patent through 2026FPI Phase 3 PEGylated interferon trialCHAMPIONS 10-year resultsCompleted Phase 2 enrollment in Ulcerative Colitis trial AutoinjectorTitrationUlcerative ColitisLong term efficacy data

Note: patent mentioned above is #7,588,755

Expanding the CD-20 Franchise 2009 2010+ PRIMA NHL 1st line maintenance resultsFPI Phase I subcutaneous formulation trialRITUXAN RA label expanded to include new claim for improvement in physical function and guidance on retreatment for TNF-IR patients Next generation molecules:GA-101 in OncologyOcrelizumab in Immunology

REACH and CLL8: relapsed and front line CLLANCA-Associated VasculitisRATE rapid infusion study

Psoriasis

Hemophilia B

Rheumatoid Arthritis

Crohn's Disease

2010 Pipeline

Daclizumab

Anti-LINGO

AVONEX

TYSABRI

Ocrelizumab

BG-12

BIIB014

Neublastin

RITUXAN

FUMADERM

Pain

Multiple Sclerosis

Multiple Sclerosis

Multiple Sclerosis

Multiple Sclerosis

Multiple Sclerosis

Parkinson's

MS

Non-Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia

Solid Tumor

Solid Tumor

RITUXAN

Galiximab

Anti-Cripto-DM4

HSP90 Inhibitor

Volociximab

Anti-IGF-1R

Lumiliximab

NEUROLOGY

ONCOLOGY

Market

Phase 1

Phase 2

Phase 3

Pre-Clinical

Market

Phase 1

Phase 2

Phase 3

Pre-Clinical

Long Acting rFactor IX

Lixivaptan

Long Acting rFactor VIII

Hyponatremia

Solid

BART

AD

Multiple Sclerosis

PEGylated-IFNb1a

NHL

GA 101

Market

Phase 1

Phase 2

Phase 3

Pre-Clinical

Market

Phase 1

Phase 2

Phase 3

Pre-Clinical

Rheumatoid Arthritis

RA

BG-12

Anti-TWEAK

Ulcerative Colitis

AVONEX

RAF Inhibitor

Fampridine-PR

Multiple Sclerosis

Lixivaptan

ANCA Associated Vasculitis

RITUXAN

Chronic Lymphocytic Leukemia

RITUXAN

Solid Tumor

TYSABRI

Ocrelizumab

Rheumatoid Arthritis

Congestive Heart Failure

Solid

Anti-FcRn

Pemphigus

AD = Alzheimer's Disease, IBD = Irritable Bowel Disease

CLL

GA 101

Hemophilia A

Non-Hodgkin's Lymphoma

GSM

AD

EMERGING

IMMUNOLOGY

NEUROLOGY

TYSABRI

Multiple Myeloma

= Progress Since 2007

IBD

TNF-TWEAK Bispecific

GRAPHIC2b79481b79481z0001.gifGRAPHIC

begin 644 b79481b79481z0001.gifM1TE&.#=AT`(%"`>!`X4$AX>!A8&B@J#A@:$!PMB&BPP%"(D$AP>!`X6#!88(#8Z&BHL$"(H#!86`@8*"AHB$AH:$!XD)CP\``HM."A08%"`D'#`V!`H."!(6&B@F"A(6"A@@+#H\$"`F%!X>'BPN(C8X"`H*#AHM/'APZTJ7\Z\N?/GM5*7J?,F3)TU&U;/OQ(Z3.Q#L+;O^6Q&X1EJ6+$/.JU_/_GRE]_`KC9A/O[[]M^_A'Q-C/O[_^_@#Z%X-^D%#BB!/PE"),@CIXX1D1@KTK9*XC'@MM\N=_$308]&?530C:JM\Y86;SN$+72B4G_S;BCM+/SB@0#G*T`&.OV*CB.@CM(2)!_$C40(^16/,(E-AOR_OX1#,G-",4'Y[#(EI&.Z>>5,K^&VGN96`J.P4_MT7^ZWN-\1>E$A:_ZWU0G.FG#'3>0*C&HJK14#^5^U&2JUK,Q?YQU_3$[0V`%M-FMZ(6I2X@H01A!IIW8KDU9M9PW+@`&40'>04(&6$`K1-C9!,136=FU-J$"M&[`+Z=``OV80"U@7=B(6$(@#KZ`&T;`,%2@%"A(&R9`,X["!-]"!:?.!L]``MZ4!XMW`%CA`*6F`(%C`J*;B"XN98+#A.-X9C.2:#@[-9DU>#Z81Y\C9/NG(KMI,5\]S1Z0@@B%1=P#U6$9W1P3.B$(Z!P7B2%#P=Q88:%ZC@@Q1(#Q?(,(U!FM)#"/OZ]:"EZ:WC@$RM'\>"F%HP!,\P`)1P#ZMP!>K0#G@0!.'@"FM8WK1R@`#28%K1[2H^JT!W*[!_\)C#:4FCG133E1/1!I4]HS=)34/9ETMKD6G2>Q:,F-Q-3U)2DI&;4V=J;1KV#ZK_P7L`-+%^QCML#/0=G]0@22+`A`0",/C!*&`+WFGE%RP%+ZX:R>T)FRP`DB``E8)`VP&`Z]`MLC!@"5S@E#2GLBO[J"P[EBYK*C&KEI;JC,Z7/)Y:*Z+%@]3^2%KY=HW86'I`MZ&6F"K5L6*H5QZI(NW!9QJ&YU67H^!_HLEL')[7A\@Q:8+7SFZM#,``P0`[XMX`"2D`NY(+9!\`.Y4*SA(`^\.%Z46B.LH>.'_J^890?R%*_M5CL$]ZL+^FL,'.`,POH#X1#`/Z`*GB`'GE`#(I=R9="LH4E;/;H'$#RWR"BIM8QPW#BDCUW,3KGFD$BFX3"H^M@D3\_IK/(PDZW-4:I$!9#`(CD`)E-`!CF!G1ZP.*.`(#MKK[5.TH]\^R$S(!^0^Y9*L!5E@[H=LCDVKT>Z;6^_X[O$N[_5.[]!`M#LA0!=QP`9CLOT%0!V#PR4RP!5``!0A`!9&`!`JL\'T_K4"6]HPG/8=6'=T4M7AOL2(Y&WH:.KNIU=%7MD8E>`"@L`H]NWRP,8*=V#M9`2_C^@U5:4M8RK"5)MDPUML^*?W@3LE^#6S#*@%`OY,-F&8BAZIWQ+2)`=0XX\21)DD2+-6!9BR3+&3"XU;(L,D(;``!K^%32`C7+D"Q9*ET=,>#G5JY=O7*="33&B+!`MMX[]^E.+EA%:GKT=$E?N7+G/[MR],P`%N27&)''@)BB[%"RB"MF"#I%CE4&YM